Grifols (GRFS) Expected to Announce Earnings on Wednesday

Grifols (NASDAQ:GRFS) is anticipated to post its quarterly earnings results on Wednesday, February 26th. Analysts expect Grifols to post earnings of $0.13 per share and revenue of $1.86 billion for the quarter.

Grifols Trading Down 0.3 %

Shares of GRFS stock opened at $7.43 on Tuesday. Grifols has a fifty-two week low of $5.30 and a fifty-two week high of $9.96. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. The stock’s fifty day moving average is $7.37 and its two-hundred day moving average is $8.09. The firm has a market capitalization of $5.11 billion, a P/E ratio of 6.35 and a beta of 0.40.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on GRFS shares. Berenberg Bank raised shares of Grifols to a “strong-buy” rating in a research note on Tuesday, October 29th. Morgan Stanley began coverage on Grifols in a report on Wednesday, February 12th. They set an “overweight” rating on the stock.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.